These in vivo results were reinforced by the in vitro findings from a panel of eight ovarian cancer cell lines in which SC66 treatment suppressed cell proliferation and invasion, and regulated COL11A1 to overcome chemoresistance and promote cell apoptosis. Here, COL11A1 is linked to ovarian carcinoma.